Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess all those charts don't mean anything at this point in the game....
It closed in the GREEN up another 3.46% on relatively low volume too. Good sign....
Friday should be another GREEN day. I like it when it heads in the right direction...
Kirk,
You need to think in the present not the distant past.
For example, if you initially bought at the low of $3.06 a few months ago then DSROYAL is absolutely correct and one would be walking around with a smile on their face.
Think of it this way.
If a shark bit you would you keep allowing it too? Or would you do something about it? Huh?
Because he was hired to be the CEO of OCATA and that would be the right thing to do as a CEO of a company....
If he cared about being a CEO of a company...Period...
Other stocks that trade on the NASDAQ are going red on this Friday too. Amazing huh...
Personally, I wouldn't let it stress me out too much. Not all stocks that trade on the market can always close green every Friday...Just simple fact...lol...
Sounds about right for the .10c to .20c drop on Monday and Tuesday unless any Tuesday news comes out then it will be okay for a few days to repeat the pattern.
Haha....Now it shows $.10 pre-market....Ohh well...Must have been a typo.....
I haven't hear anything but I am showing it up $1.10 pre market too.
Something going on....
Perhaps he needs to be more like putin..
I just called OCATA at 508-756-1212 and then hit option 0 for immediate assistance.
The phone rang 3 times and a lady named Tanya immediately answered and asked how she could help me.
I guess that blows wind up that MAKO article for sure...
Don't believe me give OCATA a call...However, I wouldn't call them at midnight which is probably what MAKO did...
Plus that picture on the door that said "Please keep the door closed" looks like it was stuck on the outside of the door.
Possibly from the MAKO clown taking the pictures?
Captain,
Personally, I would not put much credence into a post from an OCATA message board.
Mind1,
Good news. It appears the October 1 Tufts paper announcement was correct after all. It just cam a little early.
See post 88895 and 88896 for further details..
Patience said the dragon fly to the fire fly to the grass hopper.
It does seem to slowly be climbing in a positive direction finally on low volume and no new news.
Perhaps the volatility has calmed and it will start trading on the GS market as it should. Which means any type of positive news should progress it slightly forward again and again as the shorts slowly cover their positions...
Best for both parties as any day could bring another smack to a MAKO student trying to short a company that is about to help society as a whole...
Now is the time to cover, pull up your shorts and cover knees while possible...IMHO...
Have a great weekend all...
You might be right.. I thought he able too and commented on one subject with Tufts and when asked about other subjects he said he could not comment on those due to CDA's?....
Unless he was able to mention only on that subject and nothing else? I guess October 1st will be the truth..
Might be some credence to it? We will see on October 1st.
If you had said it came from the MAKO joke of a paper I would have laughed it off...
I always thought their was something fishy about that MAKO article that was filled with erroneous information regarding OCATA.
http://www.bizjournals.com/boston/blog/bioflash/2015/09/beverly-biotech-fights-back-calls-lawsuit.html?ana=yahoo
I agree. IMO SA is biased based on the writers view point. I mean just look at that last joke of an article by MAKO.
Quick 2015 Recap from another poster I thought was worth sharing:
September 8, 2015
First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD
September 3, 2015
Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer
September 1, 2015
Ocata Therapeutics Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa
August 31, 2015
Ocata Therapeutics Appoints Dr. Brian Levy to its Board of Directors
August 24, 2015
Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis
August 19, 2015
Ocata Therapeutics Secures $10 Million in Debt Financing
July 15, 2015
Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
July 14, 2015
Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus
July 1, 2015
Ocata Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
June 30, 2015
Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices
June 24, 2015
Ocata Therapeutics Announces Positive Results Reported in a Late Breaking Abstract at the Annual Meeting of the International Society for Stem Cell Research
June 18, 2015
Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015
June 16, 2015
Ocata Therapeutics Announces Pricing of $30 Million Offering of Common Stock and Warrants
June 2, 2015
Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases
May 26, 2015
Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
May 18, 2015
Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
May 11, 2015
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum
April 30, 2015
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
April 28, 2015
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to Deliver Opening Address at the Massachusetts State Science & Engineering Fair
March 31, 2015
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
March 24, 2015
Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from Allele Biotechnology and Extends Leadership Position in Cell Therapy Capabilities
March 17, 2015
Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency
February 26, 2015
Ocata Therapeutics Approved for Listing on NASDAQ
February 25, 2015
Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology
February 24, 2015
Ocata Therapeutics to Present at 2015 Cowen Health Care Conference
February 11, 2015
Ocata Therapeutics Withdraws Offering of Common Stock
February 4, 2015
Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
February 3, 2015
Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
Well they wanted me to talk dumb MAKoS and such,
Personally It don't rub me the right way...How about you?
And now you know all,,,, Of silly history...
H
a
r
v
a
r
d
s
a
y
s
s
o
Gotta respect it
Chitty shitty hang bang....yeah...Yeah...
G2 says all is all write, right as donkeys dream of suckers....
burppityy...Care about U2....
Is it better to be rich or famous?
E.g. My name is Robert Lanza and I enjoy being both...
Carry on my wayward sons....
And know Paul Harvey has explained the rest of the story to allness
That is funny...
Is that burp mixed with a tad of white lightening?
Farviewhill,
The NIH grant was for $225,639. This is 50 % higher than normally offered for a phase 1 offer which usually isn't more than $150,000. The link below will give you some information:
http://projectreporter.nih.gov/project_info_details.cfm?aid=8973041&icde=25939146&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC
Here is some additional information from another board poster that might be of interest:
The Small Business Innovation Research (SBIR) program is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development (R/R&D) that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological potential and provides the incentive to profit from its commercialization. By including qualified small businesses in the nation's R&D arena, high-tech innovation is stimulated and the United States gains entrepreneurial spirit as it meets its specific research and development needs.
The SBIR Program is structured in three phases:
Phase I. The objective of Phase I is to establish the technical merit, feasibility, and commercial potential of the proposed R/R&D efforts and to determine the quality of performance of the small business awardee organization prior to providing further Federal support in Phase II. SBIR Phase I awards normally do not exceed $150,000 total costs for 6 months.
Phase II. The objective of Phase II is to continue the R/R&D efforts initiated in Phase I. Funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the project proposed in Phase II. Only Phase I awardees are eligible for a Phase II award. SBIR Phase II awards normally do not exceed $1,000,000 total costs for 2 years.
Phase III. The objective of Phase III, where appropriate, is for the small business to pursue commercialization objectives resulting from the Phase I/II R/R&D activities. The SBIR program does not fund Phase III. Some Federal agencies, Phase III may involve follow-on non-SBIR funded R&D or production contracts for products, processes or services intended for use by the U.S. Government.
Vacuum and minefields....WOW 'El c...
Would it be possible to hear a lightening bolt crack in space?
Ahhh...It is all great El' C......I live on a different side of the earth from you and the sunlight is starting to come up from...
May everyone be happy and fortunate, as OCATA did close in the green, on a really bad market down day.....And on a Friday.....
Which tells me to sell on Monday......IMO only....
Pilate...
Thanks.....
L
M
A
O
Ben awhile thank you again....
Chuck,
I sort of agree with you however at the same time I am perplexed of what OCATA had to give up to ensure that $10 million dollar loan.
Do you you think they will be able to deliver on the payments in proper due time? Else, give some of their hard earned proprietary secrets away to settle the debt?
Hello fairviewhill,
I agree with your zero reason statement...
HI El'C....
Nothing wrong with being correct now & then...
Time zone wizards at their best.....Very accurate...and right....
I admire the dedication it involves....
RM time works too...
Elk,
HUA...Gas, also called the drop too the low $3 range several weeks ago
Spot on....Gas,
Stay safe...
Gas...
You rocked it correctly...WOW...
Absolutely...
3 for 3.....Nice....
Hi,
According to the WSJ (Wall Street Journal) normal shorts are approximately 1.4 million shares short.. Not much on approx. 42 million...
http://quotes.wsj.com/OCAT
however, this does not include naked shorts like Miss. Dukes ...AMEN.
Imagine if some great news broke out next Tuesday 08.25.15....A lot of covers would be sold to remain in the safe zone..
Absolutely,
E.G. We recently received FDA approval for a pink pill designed for woman to make them feel more excited....Will be bought out/sold off for a huge profit too?...
We designed a cure for this type of cancer....Might be sold off in phase II for a huge profit to the employees with a signed NDA and.. No one ever hears anymore about it anymore...
OT: We have developed a breathing intake apparatus for a car (Carburetor) that mixes a swirl of H20 and O2 and can achieve 500 mpg.....(Signed off again...Intellectual property et al;...yadda..yadaa... and no one ever hears about it again)...
However, IMHO as long as Lanza is with OCATA and directing the ship we should be okay....
However, he is not getting any younger and has made enough to retire, right now, if he chose too.
Of course he hasn't due to not been selected for a Nobel award or achieved the status of one of his mentors named Jonas Salk yet...
So...I believe he will stick it out until minimum of 2020 or sooner...
Once he gets his recognition he will retire....
Faster than a +/-quark that thinks it can see the force of a non-mass bosom neutrino with no spin...IMHO....
Aye, I understand..
My uhhmm..scenarios descriptions to the other post are real situations that could occur and would place a brick in the critical pathway of OCATA reaching their ultimate milestones in any year??
Believe me there is so much else involved. Even if approved, Doctors would still have to be trained on a relatively simple needle injection process into the fovea in the proper dosage for maximum coalescence.... yadda, yadda....
Which to me, Makes sense that OCATA has recently hired the 3 marketers (pun intended) to smooth the pathway in a few years.....
In other words OCATA is finally thinking out of the past box, looking into the future box, crossing their T's and setting up a facility to supply the market base that will come a calling (IF they receive FDA approval in 2019/2020).
And yes...It could be sooner if the EMA slides them in around 2017-2018....Then the FDA should follow in suit way before 2019-2020....
My few cents in the biggest down market in the last 18 months in a nut shell for now....